The Effects of Olanzapine on Genome-wide DNA Methylation in the Hippocampus and Cerebellum

Overview

Journal Clin Epigenetics

Publisher Biomed Central

Specialty Genetics

Date 2014 Jan 3

PMID 24382160

Citations 33

Authors

Melkaye G Melka

Benjamin I Laufer

Patrick McDonald

Christina A Castellani

Nagalingam Rajakumar

Richard OReilly

Shiva M Singh

Affiliations

Soon will be listed here.

Abstract

Background: The mechanism of action of olanzapine in treating schizophrenia is not clear. This research reports the effects of a therapeutic equivalent treatment of olanzapine on DNA methylation in a rat model in vivo.Genome-wide DNA methylation was assessed using a MeDIP-chip analysis. All methylated DNA immunoprecipitation (MeDIP), sample labelling, hybridization and processing were performed by Arraystar Inc (Rockville, MD, USA). The identified gene promoters showing significant alterations to DNA methylation were then subjected to Ingenuity Pathway Analysis (Ingenuity System Inc, CA, USA).

Results: The results show that olanzapine causes an increase in methylation in 1,140, 1,294 and 1,313 genes and a decrease in methylation in 633, 565 and 532 genes in the hippocampus, cerebellum and liver, respectively. Most genes affected are tissue specific. Only 41 affected genes (approximately 3%) showed an increase and no gene showed a decrease in methylation in all three tissues. Further, the two brain regions shared 123 affected genes (approximately 10%). The affected genes are enriched in pathways affecting dopamine signalling, molecular transport, nervous system development and functions in the hippocampus; ephrin receptor signalling and synaptic long-term potentiation in the cerebellum; and tissue morphology, cellular assembly and organization in the liver. Also, the affected genes included those previously implicated in psychosis.

Conclusions: The known functions of affected genes suggest that the observed epigenetic changes may underlie the amelioration of symptoms as well as accounting for certain adverse effects including the metabolic syndrome. The results give insights into the mechanism of action of olanzapine, therapeutic effects and the side effects of antipsychotics.

Citing Articles

A novel approach for target deconvolution from phenotype-based screening using knowledge graph.

Wang X, Zhang M, Xu J, Li X, Xiong J, Cao H Sci Rep. 2025; 15(1):2414.

PMID: 39827292 PMC: 11742725. DOI: 10.1038/s41598-025-86166-w.

Psychotic symptoms associated increased CpG methylation of metabotropic glutamate receptor 8 gene in Chinese Han males with schizophrenia and methamphetamine induced psychotic disorder: a longitudinal study.

Dong H, Luo T, Yang C, Liu M, Shen Y, Hao W Schizophrenia (Heidelb). 2024; 10(1):91.

PMID: 39384625 PMC: 11464599. DOI: 10.1038/s41537-024-00506-9.

DNA methylation and histone modifications associated with antipsychotic treatment: a systematic review.

Marques D, Vaziri N, Greenway S, Bousman C Mol Psychiatry. 2024; 30(1):296-309.

PMID: 39227433 DOI: 10.1038/s41380-024-02735-x.

Olanzapine's effects on hypothalamic transcriptomics and kinase activity.

Pereira S, Castellani L, Kowalchuk C, Alganem K, Zhang X, Ryan W Psychoneuroendocrinology. 2024; 163:106987.

PMID: 38340539 PMC: 10947847. DOI: 10.1016/j.psyneuen.2024.106987.

Building better brains: the pleiotropic function of neurotrophic factors in postnatal cerebellar development.

Boxy P, Nykjaer A, Kisiswa L Front Mol Neurosci. 2023; 16:1181397.

PMID: 37251644 PMC: 10213292. DOI: 10.3389/fnmol.2023.1181397.

References

Lorincz M, Dickerson D, Schmitt M, Groudine M . Intragenic DNA methylation alters chromatin structure and elongation efficiency in mammalian cells. Nat Struct Mol Biol. 2004; 11(11):1068-75. DOI: 10.1038/nsmb840. View

Bardgett M, Humphrey W, Csernansky J . The effects of excitotoxic hippocampal lesions in rats on risperidone- and olanzapine-induced locomotor suppression. Neuropsychopharmacology. 2002; 27(6):930-8. DOI: 10.1016/S0893-133X(02)00376-7. View

Geyer M, Braff D, Swerdlow N . Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl). 2001; 156(2-3):117-54. DOI: 10.1007/s002130100811. View

Muller D, Kennedy J . Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics. 2006; 7(6):863-87. DOI: 10.2217/14622416.7.6.863. View

Clark S, Adkins D, van den Oord E . Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine. Schizophr Res. 2011; 132(2-3):114-20. PMC: 3195895. DOI: 10.1016/j.schres.2011.07.031. View

Grace A . Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia. Neuropharmacology. 2011; 62(3):1342-8. PMC: 3179528. DOI: 10.1016/j.neuropharm.2011.05.011. View

Tsankova N, Berton O, Renthal W, Kumar A, Neve R, Nestler E . Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci. 2006; 9(4):519-25. DOI: 10.1038/nn1659. View

Shimizu H, Iwayama Y, Yamada K, Toyota T, Minabe Y, Nakamura K . Genetic and expression analyses of the STOP (MAP6) gene in schizophrenia. Schizophr Res. 2006; 84(2-3):244-52. DOI: 10.1016/j.schres.2006.03.017. View

Zhang D, Cheng L, Badner J, Chen C, Chen Q, Luo W . Genetic control of individual differences in gene-specific methylation in human brain. Am J Hum Genet. 2010; 86(3):411-9. PMC: 2833385. DOI: 10.1016/j.ajhg.2010.02.005. View

10.

Melas P, Rogdaki M, Osby U, Schalling M, Lavebratt C, Ekstrom T . Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset. FASEB J. 2012; 26(6):2712-8. DOI: 10.1096/fj.11-202069. View

11.

Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12):1209-23. DOI: 10.1056/NEJMoa051688. View

12.

van Rossum J . The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther. 1966; 160(2):492-4. View

13.

Ide M, Lewis D . Altered cortical CDC42 signaling pathways in schizophrenia: implications for dendritic spine deficits. Biol Psychiatry. 2010; 68(1):25-32. PMC: 2900524. DOI: 10.1016/j.biopsych.2010.02.016. View

14.

Schreiner A, Niehaus D, Shuriquie N, Aadamsoo K, Korcsog P, Salinas R . Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial. J Clin Psychopharmacol. 2012; 32(4):449-57. DOI: 10.1097/JCP.0b013e31825cccad. View

15.

Gray R . Olanzapine: efficacy in treating the positive and negative symptoms of schizophrenia. Ment Health Care. 1998; 1(6):193-4. View

16.

Deng C, Lian J, Pai N, Huang X . Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model. J Psychopharmacol. 2012; 26(9):1271-9. DOI: 10.1177/0269881112449396. View

17.

Szyf M . Epigenetic therapeutics in autoimmune disease. Clin Rev Allergy Immunol. 2009; 39(1):62-77. DOI: 10.1007/s12016-009-8172-8. View

18.

Dong E, Nelson M, Grayson D, Costa E, Guidotti A . Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc Natl Acad Sci U S A. 2008; 105(36):13614-9. PMC: 2533238. DOI: 10.1073/pnas.0805493105. View

19.

Muller D, Muglia P, Fortune T, Kennedy J . Pharmacogenetics of antipsychotic-induced weight gain. Pharmacol Res. 2004; 49(4):309-29. DOI: 10.1016/j.phrs.2003.05.001. View

20.

Jasovic-Gasic M, Vukovic O, Pantovic M, Cvetic T, Maric-Bojovic N . Antipsychotics--history of development and field of indication, new wine--old glassess. Psychiatr Danub. 2012; 24 Suppl 3:S342-4. View